Tarsus Pharmaceuticals, Inc.
TARS· Nasdaq
Released Mar 14, 2022, after the close
10-K filed Mar 14, 2022, 73 days after period end · 0001819790-22-000010
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|
| Revenue | $338.00K | $0.00 | — |
| Net Income | -$14.85M | -$11.47M | -$1.41M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR